Douglas K. Spracklin

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Angela C. Doran, R. Scott Obach, Bill J. Smith et al. · Drug Metabolism and Disposition · 2004 · 440 citations

Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139

Thomas A. Lanz, Michael J. Karmilowicz, Kathleen M. Wood et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 133 citations

Cytochrome P450 2E1 is the Principal Catalyst of Human Oxidative Halothane Metabolism in Vitro

Douglas K. Spracklin, Douglas C. Hankins, Jeannine M. Fisher et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 121 citations

Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs

Raman Sharma, Timothy J. Strelevitz, Hongying Gao et al. · Drug Metabolism and Disposition · 2011 · 112 citations

Discovery of Two Clinical Histamine H ₃ Receptor Antagonists: <i>trans</i> - <i>N</i> -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and <i>trans</i> -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- <i>N</i> -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)

Travis T. Wager, Betty Pettersen, Anne W. Schmidt et al. · Journal of Medicinal Chemistry · 2011 · 107 citations · Full text